Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Olumiant for Rheumatoid Arthritis

Eli Lilly, Incyte news release; 2018 Jun 1

Eli Lilly and Company and Incyte Corporation have announced that the US Food and Drug Administration (FDA) has approved the 2-mg dose of Olumiant (baricitinib)—a once-daily, oral, Janus kinase (JAK) inhibitor—for the treatment of adults with moderately-to-severely active rheumatoid arthritis (RA) who have had an inadequate response to ≥1 tumor necrosis factor (TNF) inhibitor therapies. Olumiant may be used as monotherapy or in combination with methotrexate (MTX) or other non-biologic disease-modifying antirheumatic drugs DMARDs. However, use of Olumiant in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants, such as azathioprine and cyclosporine, is not recommended.

Eli Lilly and Company is headquartered in Indianapolis, IN; Incyte Corporation is based in Wilmington, DE.

Adverse reactions: Adverse reactions (≥1%) include upper respiratory tract infections, nausea, herpes simplex, and herpes zoster.

Citation:

FDA approves Olumiant (baricitinib) 2-mg tablets for the treatment of adults with moderately-to-severely active rheumatoid arthritis. [news release]. Indianapolis, IN: Eli Lilly and Company, and Wilmington, DE: Incyte Corporation. June 1, 2018. https://investor.lilly.com/news-releases/news-release-details/fda-approves-olumiantr-baricitinib-2-mg-tablets-treatment-adults. Accessed July 3, 2018.

This Week's Must Reads

NSAIDs Linked with Increased Stress Fracture Risk, J Bone Miner Res; ePub 2018 Oct 23; Hughes, et al

Knee Pain and Physical Activity Preference Examined, Osteoarthritis Cartilage; ePub 2018 Oct 15; Pinto, et al

Age at Menarche Linked to Osteoporosis Etiology, Bone; 2018 Dec; Zhang, Greenbaum, Zhang, et al

Link Found Between Viral Pathogens and Arthritis, Int J Rheumatol; 2018 Oct 1; Shmagel, et al

Diabetics Show Accelerated Knee Joint Degeneration, Skeletal Radiol; ePub 2018 Oct 24; Neumann, et al

Must Reads in FDA Actions

FDA Approves Subcutaneous Actemra for Active SJIA, PharmaLive news release; 2018 Sep 13

FDA Approves Olumiant for Rheumatoid Arthritis, Eli Lilly, Incyte news release; 2018 Jun 1

FDA Approves Consensi for Osteoarthritis Pain, FirstWord Pharma news release; 2018 May 31

FDA Approves Prolia for GIOP in Men and Women, FirstWord Pharma news release; 2018 May 21

FDA Approves Xeljanz/Xeljanz XR for Adult PsA, Pfizer news release; 2017 Dec 14